13.25

2.16% 0.28

After Hours: 13.30 0.05 +0.38%

Contineum Therapeutics Inc (CTNM)

Overview News Price History Discussions Forecast

Contineum Therapeutics Inc stock is traded at $13.25, with a volume of 1.15M. It is up +2.16% in the last 24 hours and up +1.92% over the past month. Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Previous Close:

$12.97

Open:

$13.03

24h Volume:

1.15M

Relative Volume:

4.08

Market Cap:

$494.70M

Revenue:

$50.00M

Net Income/Loss:

$-59.98M

P/E Ratio:

-6.068

EPS:

-2.1836

Net Cash Flow:

$-55.54M

1W Performance:

+3.60%

1M Performance:

+1.92%

6M Performance:

+7.55%

1Y Performance:

+222.38%

1-Day Range:

$12.90

$13.46

1-Week Range:

$12.56

$13.46

52-Week Range:

$3.35

$16.33

Contineum Therapeutics Inc Stock (CTNM) Company Profile

Name

Contineum Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(858) 333-5280

Address

3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CTNM's Discussions on Twitter

Compare CTNM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTNM Contineum Therapeutics Inc	13.25	484.25M	50.00M	-59.98M	-55.54M	-2.1836
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-13-25	Initiated	Leerink Partners	Outperform
Sep-25-25	Initiated	Leerink Partners	Outperform
Jun-20-25	Initiated	William Blair	Outperform
Oct-22-24	Initiated	Robert W. Baird	Outperform
Apr-30-24	Initiated	Morgan Stanley	Overweight
Apr-30-24	Initiated	RBC Capital Mkts	Outperform
Apr-30-24	Initiated	Stifel	Buy

View All

Contineum Therapeutics Inc Stock (CTNM) Latest News

Apr 06, 2026

Bank Watch: Can Contineum Therapeutics Inc stock outperform in a bear marketWeekly Trade Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Apr 06, 2026

Contineum Therapeutics CSO sells $56k in CTNM stock - Investing.com UK

Apr 06, 2026

Pre-planned stock sale by Contineum (CTNM) chief scientific officer - Stock Titan

Apr 06, 2026

Daniel Lorrain sells via 10b5-1; CTNM (NASDAQ: CTNM) Form 144 notice - Stock Titan

Apr 06, 2026

Apr 01, 2026

CTNM Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 01, 2026

Mar 30, 2026

Contineum (CTNM) Q2 R&D Jumps 78% - aol.com

Mar 30, 2026

Mar 29, 2026

MACD Signal: Can Contineum Therapeutics Inc stock outperform in a bear market2026 Volume & Low Volatility Stock Recommendations - baoquankhu1.vn

Mar 29, 2026

Mar 27, 2026

Guidance Update: Is Contineum Therapeutics Inc currently under institutional pressure2026 Opening Moves & Stepwise Trade Signal Guides - baoquankhu1.vn

Mar 27, 2026

Sentiment Review: Is Contineum Therapeutics Inc currently under institutional pressureWeekly Investment Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn

Mar 27, 2026

We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth - 富途牛牛

Mar 27, 2026

Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth - simplywall.st

Mar 27, 2026

Retail Trends: What is the Moat Score of Contineum Therapeutics Inc2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn

Mar 27, 2026

Mar 26, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Mar 26, 2026

Mar 25, 2026

Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% HigherStill a Buy? - MarketBeat

Mar 25, 2026

Mar 22, 2026

Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 22, 2026

Mar 19, 2026

Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn

Mar 19, 2026

Contineum Therapeutics, Inc.Common stock (NQ: CTNM - The Chronicle-Journal

Mar 19, 2026

Mar 17, 2026

Revenue Check: Is FKWL still a buy after recent gainsStock Surge & Detailed Earnings Play Alerts - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference - Defense World

Mar 16, 2026

Mar 15, 2026

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 13, 2026 - BioSpace

Mar 15, 2026